RE:Conference CallIm still flummoxed with todays quarterly report.
Matt declared ONC a Breast Cancer company many years ago. There was genuine excitement about the outcome of the IND213 trial and the massive size of the therapeutic market it represented.
I dont know what the opportunity has become with todays news. But i would guess poor design of the Bracelet trial has now reduced the market potential seven fold. From the Type C meeting, pelas knew patient population is subjugate to ADC treatment and only those patients who drop out after a single ADC treatment do to adverse reaction. Im "guessing" that 15 % drop out.
ONC must now run a new phase 2 trial to see how pela performs. This hammers revenue potential and adds years and risk to the Breast Cancer opportunity.
This is why i declared ONC a pancreatic cancer company. Meaning their priority is now to get pela treament of pancreatic to market asap. Cost of combination treatment with ICI maybe an issue for them. With the ICI and pela demanding 150k$ each?
Im hard on ONC for failure to incorporate Tylenol treatment protocal in the Bracelet trial design to help patients with flu like symptoms. If i dawned a conspiracy theorist hat i might suggest Pfizer intentionally threw the pela paclitaxol arm of the Bracelt trial. Something stinks about primary investigators and patients dropping with flu like symptoms. It just doesnt add up.
Ill finish on a positive. They are moving towards a Q1 2025 first enrollment for i think an adaptive phase 2/3 pancreatic trial? I hope this means partnership and income deal this year. And an outside shot at a sale.
If i was ONC, id also be working Adele to initiate a Breast Cancer trial for the asian market on the original treatment group. To circumvent FDA instruction, to prove concept of AWARE patient typing and prove therapeutic as first line treatment for Breast Cancer over and above ADCs.
Rambling thoughts.